Description: Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life sciences research products and services. It operates in three segments: Bio-Science Services and Products, Industrial Synthetic Biology Products, and Precision Immune-Cell Therapy. The Bio-Science Services and Products segment provides life sciences research services in various categories, including gene synthesis, oligonucleotide synthesis, DNA sequencing, protein production, peptide synthesis, and antibody development; life sciences research catalogue products, such as pre-packaged, ready-to-use, and off-the-shelf products comprising antibodies, recombinant proteins, reagent products, and small equipment for protein expression and analysis; and preclinical drug development services, including integrated contract research services in categories comprising antibody and protein engineering, in vitro pharmacology service, and in vivo pharmacology service. The Industrial Synthetic Biology Products segment produces industrial enzymes used in various industries, such as food processing, feed, pharmaceutical, and chemical industries. The Precision Immune-Cell Therapy segment discovers and develops therapies for the treatment of liquid tumors through optimized chimeric antigen receptor structures; and develops bispecific chimeric antigen receptor T-cell therapies. Genscript Biotech Corporation primarily serves pharmaceutical and biotech companies, colleges and universities, research institutes, and government bodies, as well as distributors located in the United States, Europe, the People's Republic of China, the Asia Pacific, and internationally. The company was founded in 2002 and is headquartered in Nanjing, China. Genscript Biotech Corporation is a subsidiary of GenScript Corporation.
Home Page: www.genscript.com
Jiangning Science Park
Nanjing,
211100
China
Phone:
86 25 5889 7288
Officers
| Name | Title |
|---|---|
| Mr. Jiange Meng | Chairman |
| Dr. Zhenyu Liu | Chief Exec. Officer |
| Ms. Ye Wang M.S. | Co-Founder, Pres & Exec. Director |
| Mr. Shiniu Wei | Chief Financial Officer |
| Ms. Weihui Shao | Chief Operating Officer |
| Dr. Li Zhu Ph.D. | Chief Strategy Officer & Exec. Director |
| Dr. Chuan-Chu Chou | Head of Discovery and Preclinical Services |
| Mr. Chifa Zhang | Department Head of Industry Synthetic Biology Product Segment |
| Dr. Brian Hosung Min | CEO of Biologics Bus. |
| Ms. Wai Ling Wong A.C.I.S., A.C.S., ACIS, ACS | Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 79.3651 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.6476 |
| Price-to-Sales TTM: | 10.8217 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5573 |